Cargando…
Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 via contrast-enhanced comp...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727688/ https://www.ncbi.nlm.nih.gov/pubmed/35004297 http://dx.doi.org/10.3389/fonc.2021.775147 |
_version_ | 1784626571818041344 |
---|---|
author | Lin, Jieheng Yang, Jianying Wang, Wenping Lin, Xiaotong Cao, Yang |
author_facet | Lin, Jieheng Yang, Jianying Wang, Wenping Lin, Xiaotong Cao, Yang |
author_sort | Lin, Jieheng |
collection | PubMed |
description | We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 via contrast-enhanced computed tomography (CT) and endoscopic biopsy. She stabilised after preoperative neoadjuvant chemotherapy, surgery, and postoperative adjuvant chemotherapy. In September 2019, positron emission tomography (PET)/CT re-examination suggested a peritoneal metastasis and multiple lymph node metastases. She then received six cycles of camrelizumab plus chemotherapy. PET/CT indicated that the metastatic foci had disappeared and that she had achieved a clinical complete response(CCR). She was followed-up with camrelizumab plus capecitabine (maintenance therapy). At the time of writing, her progression-free survival is more than 14 months and her quality of life is good. Thus, camrelizumab plus chemotherapy is a useful first-line treatment for HER2- and PD-L1-negative advanced gastric adenocarcinoma. |
format | Online Article Text |
id | pubmed-8727688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87276882022-01-06 Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report Lin, Jieheng Yang, Jianying Wang, Wenping Lin, Xiaotong Cao, Yang Front Oncol Oncology We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 via contrast-enhanced computed tomography (CT) and endoscopic biopsy. She stabilised after preoperative neoadjuvant chemotherapy, surgery, and postoperative adjuvant chemotherapy. In September 2019, positron emission tomography (PET)/CT re-examination suggested a peritoneal metastasis and multiple lymph node metastases. She then received six cycles of camrelizumab plus chemotherapy. PET/CT indicated that the metastatic foci had disappeared and that she had achieved a clinical complete response(CCR). She was followed-up with camrelizumab plus capecitabine (maintenance therapy). At the time of writing, her progression-free survival is more than 14 months and her quality of life is good. Thus, camrelizumab plus chemotherapy is a useful first-line treatment for HER2- and PD-L1-negative advanced gastric adenocarcinoma. Frontiers Media S.A. 2021-12-22 /pmc/articles/PMC8727688/ /pubmed/35004297 http://dx.doi.org/10.3389/fonc.2021.775147 Text en Copyright © 2021 Lin, Yang, Wang, Lin and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Lin, Jieheng Yang, Jianying Wang, Wenping Lin, Xiaotong Cao, Yang Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report |
title | Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report |
title_full | Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report |
title_fullStr | Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report |
title_full_unstemmed | Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report |
title_short | Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report |
title_sort | clinical complete remission of an advanced gastric adenocarcinoma after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727688/ https://www.ncbi.nlm.nih.gov/pubmed/35004297 http://dx.doi.org/10.3389/fonc.2021.775147 |
work_keys_str_mv | AT linjieheng clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport AT yangjianying clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport AT wangwenping clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport AT linxiaotong clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport AT caoyang clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport |